Jimmy Chang

CEO at TaiMed Biologics

Presenter

TaiMed Biologics is a publicly listed biotechnology company headquartered in Taipei, Taiwan, dedicated to developing and commercializing innovative biologics that address urgent unmet medical needs. Founded in 2007, TaiMed has built a global reputation as a pioneer in HIV monoclonal antibody therapeutics, with proven capabilities spanning discovery, clinical development, regulatory approval, and large-scale biologics manufacturing. Our flagship product, Trogarzo® (ibalizumab-uiyk), is the world’s first and only FDA-approved monoclonal antibody for the treatment of multidrug-resistant HIV. Trogarzo® was developed in Taiwan and launched in the United States and Europe — marking a historic milestone as the first biologic developed and commercialized by a Taiwanese company for a global market. Building on this foundation, TaiMed is advancing a next-generation HIV portfolio, including TMB-365/TMB-380, a long-acting combination biologic therapy designed to transform HIV maintenance treatment by reducing dosing frequency and improving patient quality of life. Beyond HIV, TaiMed is leveraging its proprietary antibody platform to develop novel antibody-drug conjugates (ADCs) for HIV and autoimmune diseases, expanding our impact into broader therapeutic areas. The company is also growing its contract development and manufacturing organization (CDMO) business, offering end-to-end biologics manufacturing solutions and investing in a new GMP facility to support both internal pipelines and external clients.